Advertisement
BMY or MRK or PFE
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Merck (MRK) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) has delivered strong growth from its portfolio of newer therapies, with Q2 2026 revenue up 6% and raised full-year guidance amid positive pipeline data.
- Merck (MRK) maintains leadership in oncology through Keytruda, posting recent regulatory approvals and consistent revenue growth of around 5% in Q2 2026, supporting elevated valuations.
- Pfizer (PFE) shows recovery in non-COVID products with 18% operational growth in launched assets and raised 2026 revenue guidance following cost-saving initiatives.
- Relative performance in recent weeks highlights MRK's outperformance on momentum, while BMY and PFE trade at more attractive valuations with higher dividend yields.
- Sector exposure remains centered on oncology and specialty pharmaceuticals, with each company navigating patent dynamics through pipeline advancement and strategic launches.
- Market sentiment reflects stability for MRK, recovery signals for PFE, and balanced growth for BMY based on observable earnings trends and recent developments.
Introduction
Investors and traders focused on the pharmaceutical sector often compare Bristol-Myers Squibb (BMY), Merck (MRK), and Pfizer (PFE) due to their significant market positions in oncology, specialty medicines, and established product portfolios. These large-cap stocks offer exposure to innovation-driven growth alongside mature franchises facing eventual patent pressures. This comparison appeals to those evaluating relative performance, valuation metrics, and momentum within the healthcare industry amid evolving regulatory and competitive landscapes. The analysis draws on recent financial results and market activity to highlight contrasts in business positioning and operational trends.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) focuses on oncology, hematology, and cardiovascular therapies, with a growing emphasis on its portfolio of newer assets. In recent market activity, the stock has shown resilience, trading near $63 following Q2 2026 results that included revenue of $13.0 billion, up 6% year over year, and raised full-year guidance. Positive developments include durable efficacy data for Sotyktu in psoriatic arthritis and new approvals such as ZENBEXUS for multiple myeloma. Sentiment has been supported by pipeline progress and dividend declarations, offsetting legacy portfolio declines, while the growth segment expanded 15% in the quarter.
MRK Overview and Recent Performance
Merck (MRK) derives substantial revenue from its oncology franchise, particularly Keytruda, alongside vaccines and animal health products. Recent performance has been robust, with shares around $147 after Q2 2026 revenue reached $16.6 billion, up 5% year over year. Key catalysts include Japanese approval of Keytruda Qlex for subcutaneous use across indications and a positive CHMP opinion for a Keytruda-Padcev combination in bladder cancer. The company has raised and narrowed 2026 guidance, reflecting pipeline momentum that has outpaced initial expectations in several programs.
PFE Overview and Recent Performance
Pfizer (PFE) maintains a broad portfolio spanning oncology, vaccines, and internal medicine, with ongoing emphasis on launched and acquired products. In recent weeks, the stock has hovered near $27.66 amid Q2 2026 results showing $15.0 billion in revenue and an operational increase in non-COVID products. The company raised the midpoint of its 2026 revenue guidance to a range of $60.5 billion to $62.5 billion, driven by 18% growth in launched assets and expanded cost-saving targets. Pipeline updates include positive Phase 3 data for LITFULO in vitiligo and priority review for Talzenna plus Xtandi in prostate cancer.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section, based on factors such as consistency, adaptability, and statistical edge. Available bots span diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, with many exhibiting win rates in the 60-80% range or annualized returns varying widely by configuration. This resource provides traders with data-driven options for automated strategies. Explore the full selection on the Trending AI Robots page for detailed statistics and deployment opportunities.
Head-to-Head Comparison
Business models differ notably: Merck (MRK) centers on a concentrated oncology engine with Keytruda providing durable revenue, while Bristol-Myers Squibb (BMY) balances growth assets against legacy declines and Pfizer (PFE) emphasizes diversification with cost discipline. Growth drivers include MRK’s rapid pipeline readouts, BMY’s new therapy launches, and PFE’s non-COVID recovery. Recent momentum favors MRK on valuation multiples and approval news, whereas BMY and PFE offer lower price-to-earnings ratios and higher dividend yields around 4% and 6%, respectively. Risk factors encompass patent cliffs for all three, with MRK facing later Keytruda exclusivity, BMY managing multiple expirations, and PFE addressing post-COVID normalization. Sector exposure remains oncology-heavy across the group, though valuation sensitivity appears higher for MRK given its premium pricing relative to peers.
Tickeron AI Verdict
Based on observable trend consistency, stability in earnings delivery, and positioning from recent pipeline and guidance updates, Tickeron’s AI would likely assign the highest probabilistic favor to Merck (MRK) in the current environment. Its sustained oncology leadership and multiple regulatory advancements provide a clearer trajectory compared with the recovery dynamics at Pfizer (PFE) or the balanced but more valuation-sensitive profile at Bristol-Myers Squibb (BMY). This assessment reflects relative momentum rather than certainty and should not be interpreted as investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BMY in downward trend: 10-day moving average moved below 50-day moving average on September 21, 2026
The 10-day moving average for BMY crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Technical Analysis (Indicators)
Bearish Trend Analysis
BMY moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Aroon Indicator for BMY entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Oscillator exited the oversold zone, 16 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 53%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 59 cases where BMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 53%.
Following a +6.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 174 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.848) is normal, around the industry mean (19.199). P/E Ratio (14.070) is within average values for comparable stocks, (34.793). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.039) settles around the average of (0.025) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
MRK in -2.49% downward trend, sliding for three consecutive days on October 13, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MRK declined for three days, in 139 of 271 cases, the price declined further within the following month. The odds of a continued downward trend are 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MRK as a result. In 47 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
MRK moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 193 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.749) is normal, around the industry mean (19.199). MRK's P/E Ratio (118.952) is considerably higher than the industry average of (34.793). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.025) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for PFE turns positive, indicating new upward trend
PFE saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 50 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 20 of 43 cases over the following month. The odds of a continued upward trend are 47%.
Following a +3.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 149 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.922) is normal, around the industry mean (19.199). P/E Ratio (37.789) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). PFE has a moderately high Dividend Yield (0.060) as compared to the industry average of (0.025). P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 21 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
BMY | MRK | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 74 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | 11 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 76 | 29 | 100 | |
SMR RATING 1..100 | 22 | 79 | 83 | |
PRICE GROWTH RATING 1..100 | 46 | 9 | 21 | |
P/E GROWTH RATING 1..100 | 65 | 2 | 5 | |
SEASONALITY SCORE 1..100 | 75 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (11) in the Pharmaceuticals Major industry is in the same range as PFE (20) and is in the same range as BMY (42). This means that MRK's stock grew similarly to PFE’s and similarly to BMY’s over the last 12 months.
MRK's Profit vs Risk Rating (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (76) and is significantly better than the same rating for PFE (100). This means that MRK's stock grew somewhat faster than BMY’s and significantly faster than PFE’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (79) and is somewhat better than the same rating for PFE (83). This means that BMY's stock grew somewhat faster than MRK’s and somewhat faster than PFE’s over the last 12 months.
MRK's Price Growth Rating (9) in the Pharmaceuticals Major industry is in the same range as PFE (21) and is somewhat better than the same rating for BMY (46). This means that MRK's stock grew similarly to PFE’s and somewhat faster than BMY’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is in the same range as PFE (5) and is somewhat better than the same rating for BMY (65). This means that MRK's stock grew similarly to PFE’s and somewhat faster than BMY’s over the last 12 months.
| BMY | MRK | PFE | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 53% | N/A | 1 day ago 58% |
| Stochastic ODDS (%) | 1 day ago 53% | 1 day ago 63% | 1 day ago 48% |
| Momentum ODDS (%) | N/A | 1 day ago 56% | 1 day ago 57% |
| MACD ODDS (%) | N/A | N/A | 1 day ago 47% |
| TrendWeek ODDS (%) | 1 day ago 56% | 1 day ago 57% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 55% | 1 day ago 57% | 1 day ago 49% |
| Advances ODDS (%) | 1 day ago 56% | 9 days ago 57% | 1 day ago 54% |
| Declines ODDS (%) | 3 days ago 54% | 3 days ago 51% | 11 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 63% | 1 day ago 58% |
| Aroon ODDS (%) | 1 day ago 54% | N/A | 1 day ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while MRK’s FA Score has 4 green FA rating(s), and PFE’s FA Score reflects 3 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- MRK’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while MRK’s TA Score has 5 bullish TA indicator(s), and PFE’s TA Score reflects 3 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 4 bearish.
- MRK’s TA Score: 5 bullish, 2 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +1.66% price change this week, while MRK (@Pharmaceuticals: Major) price change was +1.97% , and PFE (@Pharmaceuticals: Major) price fluctuated +5.82% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.02%. For the same industry, the average monthly price growth was -4.09%, and the average quarterly price growth was +3.67%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
MRK is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.02% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with JNJ. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then JNJ could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | -1.48% | ||
| JNJ - MRK | 50% Loosely correlated | -0.25% | ||
| GSK - MRK | 50% Loosely correlated | +2.40% | ||
| AMGN - MRK | 47% Loosely correlated | +1.86% | ||
| NVS - MRK | 47% Loosely correlated | +2.38% | ||
| BIIB - MRK | 46% Loosely correlated | +1.08% | ||
More | ||||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +0.79% | ||
| BMY - PFE | 55% Loosely correlated | +2.18% | ||
| AMGN - PFE | 52% Loosely correlated | +1.86% | ||
| BIIB - PFE | 48% Loosely correlated | +1.08% | ||
| NVS - PFE | 47% Loosely correlated | +2.38% | ||
| SNY - PFE | 47% Loosely correlated | +1.31% | ||
More | ||||